publications

Researching the future of brain-based mental health care

Wave supports and contributes to a growing body of scientific research exploring the future of brain-based mental health care.

Our research library includes both independent publications and Wave-sponsored clinical studies focused on advancing the science of personalized neuromodulation and improving our understanding of how individualized brain-based interventions may support mental health outcomes.

All
Condition
Study Type
Research Focus
Population
Technology / Approach
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tag field
|
Tag value
PTSD
Observational / Retrospective Study
Neuromodulation / TMS
Veterans
MeRT® / EEG-Guided TMS

Alterations of Resting Arterial Spin Labeling Perfusion in Veterans and First Responders with Post-Traumatic Stress Disorder Following an Open-Label eTMS Treatment Protocol

Date published
November 2026
Publication
Psychiatry Research: Neuroimaging
Authors
Kelsie Pyle, Megan Hildreth, Bill Phillips, Adele M.K. Gilpin, W. Jerry Mysiw, Sudeep Pandey, Lohith Suresh, Cody Clark, Matthew S. Sherwood
Key Takeaways
  • Brain Changes Correlated with Symptom Improvement: Greater increases in blood flow in the left amygdala and hippocampus were significantly associated with larger reductions in PTSD symptoms.
  • Significant Reduction in PTSD Symptoms: Following 20 eTMS treatments, participants experienced an average 29.25-point reduction in PCL-5 scores (p < 0.001).
  • Clinically Meaningful Improvement: 88% of participants (14 of 16) experienced a clinically significant reduction of at least 10 points in PTSD symptom severity.
  • Measurable Changes in Brain Function: MRI scans revealed significant increases in resting blood flow in the amygdala and hippocampus, regions involved in emotional regulation, fear processing, and memory.
  • Brain Activity Approached Healthy Reference Levels: Before treatment, participants demonstrated significantly lower resting blood flow in the left amygdala and hippocampus compared with a separate healthy group. Following treatment, these differences were no longer statistically significant.
Read article
PTSD
Randomized Controlled Trial
Clinical Outcomes
EEG & Brain Biomarkers
Veterans
MeRT® / EEG-Guided TMS

Personalized electrophysiology-guided transcranial magnetic stimulation in post-traumatic stress disorder: a randomized, double-blind, sham-controlled study

Date published
October 2026
Publication
Personalized Medicine in Psychiatry
Authors
Alexander Taghva, Jeffery Lindquist, Anthony Kim
Key Takeaways
  • Randomized, double-blind, sham-controlled pilot study evaluating personalized, EEG-guided rTMS (MeRT) in 73 military veterans with PTSD (36 active, 37 sham) over 10 treatment sessions in two weeks.
  • Significant reduction in PTSD symptom severity: Active treatment achieved a 33.9% reduction in PCL-M scores (22.4-point mean improvement) in just two weeks, compared to 24.0% (15.9 points) with sham (p=0.049).
  • 78% achieved clinically meaningful PTSD improvement: 28 of 36 active-treatment participants experienced a ≥10-point PCL-M reduction, compared to 49% (18 of 37) receiving sham (p=0.01).
  • Significant improvement in sleep quality: Active treatment reduced PSQI-A scores by 43.9%, compared to 16.4% with sham (p=0.030). Depression symptom improvements did not significantly differ between groups (p=0.130).
  • No severe adverse events reported: Side effects were mild, most commonly headaches, which resolved within one week without medical intervention.

‍

Read article
PTSD
Randomized Controlled Trial
Clinical Outcomes
Adults
MeRT® / EEG-Guided TMS

FDA 510(k) Clearance of the MeRT System for PTSD: Pivotal Double-Blind Randomized Controlled Trial (MRT-005) — K260402

Date published
June 2026
Publication
U.S. FDA 510(k) Premarket Notification database (regulatory clinical summary; peer-reviewed publication forthcoming)
Authors
Wave Neuroscience, Inc. (sponsor); FDA 510(k) Summary, K260402
Key Takeaways
  • First FDA-cleared personalized, EEG-guided TMS treatment: cleared June 3, 2026 as an adjunct treatment for PTSD in adults (FDA Breakthrough Device Designation, November 2024).
  • Multi-site, prospective, double-blind, randomized, sham-controlled pivotal trial; intention-to-treat n=158 (77 active, 81 sham), 20–25 sessions, 84% completion.
  • Primary endpoint met: significant PCL-5 improvement vs sham (p<0.046); clinician-administered CAPS-5 separation stronger (p<0.0006) — the first randomized controlled trial in which personalized TMS separated from sham for PTSD.
  • Active-arm PCL-5 improvement of 27 points, roughly two to three times the established 8.5–12.5-point minimal clinically important difference; 68.2% of the active group met remission criteria at follow-up F2.
  • Zero serious adverse events; improvement durable through the 2–4 month follow-up window.
Read article
Autism
Sleep
Randomized Controlled Trial
Clinical Outcomes
Adolescents / Pediatric
MeRT® / EEG-Guided TMS

Evaluating the effect of repetitive transcranial magnetic stimulation on sleep difficulties in children with autism spectrum disorder: a randomized controlled trial

Date published
December 2025
Publication
SLEEP Advances (Sleep Research Society / Oxford University Press)
Authors
Ezedinma U, Burgess S, Jones E, Singh J, Ladhams A, Campbell G, Fjaagesund S, Swierkowski P, Adeyinka AA, Metse AP, Downer T, Oprescu F
Key Takeaways
  • Randomized controlled trial: 20 children (ages 6–12) with level-2 autism assigned 1:1 to immediate alpha rhythm-guided rTMS (ten sessions over two weeks) or waitlist control, with crossover.
  • Treatment group improved significantly more than controls on total Children's Sleep Habits Questionnaire score (p=.008) and on bedtime resistance (p=.003), sleep-onset delay (p=.004), and sleep duration (p=.003).
  • Objective confirmation at crossover: polysomnography showed reduced wake-after-sleep-onset (p=.014), improved sleep efficiency (p=.046), and improved N2 stage (p=.039).
  • Improvements persisted to the four-month follow-up (actigraphy wake-after-sleep-onset significant at one and four months); side effects were mild and transient.
  • First randomized controlled trial of the alpha-guided (MeRT) protocol for sleep difficulties in pediatric autism (ANZCTR: ACTRN12623000757617).
Read article
Autism
Mechanistic / Biomarker Research
EEG & Brain Biomarkers
Adolescents / Pediatric
MeRT® / EEG-Guided TMS

Alpha rhythm-guided repetitive transcranial magnetic stimulation effect on the alpha rhythms of children with autism spectrum disorder – an exploratory EEG study (preprint)

Date published
September 2025
Publication
medRxiv (preprint; not yet peer-reviewed)
Authors
Uchenna Ezedinma, Evan Jones, Alexander Ring, Scott Burgess, Jyoti Singh, Andrew Ladhams, Gary Campell, Shauna Fjaagesund, Piotr Swierkowski, Alexandra Metse, Terri Downer, Florin Oprescu
Key Takeaways
  • Exploratory EEG companion to the randomized sleep trial (20 children with ASD, ages 6–12): does alpha-guided rTMS engage its purported target, the individual alpha rhythm itself?
  • Treated children showed a significant increase in mean frontal individual alpha frequency (9.09 Hz to 9.35 Hz; p=0.021) compared with waitlist controls.
  • Decreased posterior-frontal differences suggested enhanced long-range functional connectivity, persisting through the four-month follow-up.
  • Direct target-engagement evidence for the personalization thesis: stimulation calibrated to a patient's alpha rhythm measurably shifts that rhythm. Co-authored with Wave Neuroscience.
Read article
PTSD
Traumatic Brain Injury / Concussion
Observational / Retrospective Study
Clinical Outcomes
Veterans
MeRT® / EEG-Guided TMS

Individually guided neuromodulation in special operator veterans with symptoms of PTSD and traumatic brain injury: preliminary data from a chart review

Date published
February 2025
Publication
Frontiers in Neurology
Authors
Frueh BC, Crowder C, Taghva A
Key Takeaways
  • Retrospective chart review of 33 male Special Operations Forces veterans with comorbid PTSD and TBI symptoms; alpha-guided rTMS delivered five days per week at each veteran's individual alpha frequency.
  • TBI symptom severity decreased an average of 54% on the Rivermead Post-Concussion Questionnaire (p<0.01); PTSD severity decreased an average of 37.6% on the PCL-5 (p<0.01).
  • Of participants above the PCL-5 screening threshold of 33, 69% no longer met clinical criteria for PTSD at the end of the program.
  • Side effects were consistent with standard TMS (most frequently headache and fatigue) — no new safety signal in a comorbid PTSD+TBI population.
Read article
Autism
Sleep
Observational / Retrospective Study
Clinical Outcomes
Adolescents / Pediatric
MeRT® / EEG-Guided TMS

Outcomes from Individual Alpha Frequency Guided Repetitive Transcranial Magnetic Stimulation in Children with Autism Spectrum Disorder — A Retrospective Chart Review

Date published
August 2024
Publication
Child Psychiatry & Human Development
Authors
Ezedinma U, Swierkowski P, Fjaagesund S
Key Takeaways
  • Retrospective chart review of 28 autistic children (ages 3–9; mean 6.1 years) who received 19 sessions of individual-alpha-frequency-guided rTMS over four weeks.
  • Individual alpha frequency shifted significantly toward the mature 10 Hz norm (to 9.4 Hz; p≤0.025) — biomarker movement alongside clinical change.
  • Autism symptoms (Childhood Autism Rating Scale) and quality of life (PedsQL 4.0) improved significantly; semi-structured interviews most often highlighted improved sleep.
  • Minor side effects (e.g., transient hyperactivity) resolved within about two hours of sessions.
Read article
PTSD
Depression
Traumatic Brain Injury / Concussion
Observational / Retrospective Study
Clinical Outcomes
Active-Duty Military
MeRT® / EEG-Guided TMS

A retrospective chart review to assess the impact of alpha-guided transcranial magnetic stimulation on symptoms of PTSD and depression in active-duty special operations service members

Date published
June 2024
Publication
Frontiers in Psychiatry
Authors
Bailar-Heath M, Burke R, Thomas D, Morrow CD
Key Takeaways
  • Retrospective chart review of an Air Force Special Operations Command Human Performance Optimization program delivering an average of 30 sessions of individualized alpha-frequency rTMS to active-duty operators following traumatic brain injury.
  • PCL-5 (PTSD) scores fell an average of 37% (p<.01) — from 42.9 to 27, below the clinical threshold of 33 for presence of PTSD.
  • PROMIS depression T-scores fell 11.3% and perceived cognitive deficits (PDQ) fell 45.5% by session 30 (both p<.01); 46% of members above depression thresholds at baseline resolved after treatment.
  • Side effects matched those commonly reported for rTMS — preliminary support for safe use in an active-duty military setting.
Read article